

Contents

1.	Introduction	1
1.1	Declarations of interest	2
2.	General considerations	2
2.1	General principles regarding the evaluation of veterinary drugs within the terms of reference of JECFA, including compounds without ADI or MRL	2
2.2	Comments on the CCRVDF document "Risk management methodologies, including risk assessment policies in the Codex Committees on Residues of Veterinary Drugs in Foods"	7
2.3	Expression of the ADI and derivation of the MRL	9
2.4	Recommendations on principles and methods in derivation of MRLs	12
2.4.1	New procedure for estimating chronic dietary intakes	15
2.5	Use of spreadsheet-based procedure for statistical evaluation of residue depletion data	16
2.6	Revised approach for the derivation of a microbiological ADI	17
2.7	Antimicrobial resistance risk assessment	18
3.	Comments on residues of specific veterinary drugs	18
3.1	Colistin	18
3.2	Erythromycin	33
3.3	Flumequine	45
3.4	Melengestrol acetate	46
3.5	Ractopamine hydrochloride	48
3.6	Trichlorfon (metrifonate)	50
3.7	Triclabendazole	59
3.8	Tylosin	65
4.	Future work	66
5.	Recommendations	66
	Acknowledgement	67
	References	67
	Annex 1	
	Reports and other documents resulting from previous meetings of the Joint FAO/WHO Expert Committee on Food Additives	69
	Annex 2	
	Recommendations on compounds on the agenda and further information required	78